

Market Update Webinar

Developing new insecticides derived from nature to achieve high impact worldwide.

4 February 2025



Company Highlights

Focused development of two new insecticides with strong commercial validation.

01. Two New Actives

Late-stage development: two insecticidal compounds **derived from nature with novel modes of action:**

- » **Flavocide®** and **Qcide®** are derived from a unique sub-type of eucalypt
- » effectiveness against some major insect pests with resistance to standard products
- » Strong drivers are increasing the demand for **safer and more environmentally friendly** products

02. Large Target Markets

Crop Protection (incl. Grain Storage), **Public Health**, **Consumer**, **Animal Health**, total addressable markets of \$31B, as **both stand-alone and combination** products¹

03. Focused Pipeline

Pipeline of eight (formulated) product opportunities:

- » Public Health – vectors for disease
- » Crop Protection, Aquaculture, Professional Turf and Ornamentals
- » Grain Storage Protection
- » Consumer (home & garden) – and now also Defense

04. Strong Partnering Progress

Three partnerships to date:

- » Clarke Mosquito (US), Evergreen Garden Care (EU, UK, AU & NZ), STK (Israel)

1. US EPA 2017, WHO 2017, Zoetis & Provue Market Research, Markets & Markets
2. Qcide® and Flavocide® are registered trademarks of Bio-Gene Technology Limited.



Bio-Gene Awarded U.S. Department of Defense Grants Totalling A\$3.0m

29 January 2025

Deployed Warfighter Protection (DWFP) program - new product opportunities in defense

The DWFP program is a U.S. Department of Defense program administered by the U.S. Armed Forces Pest Management Board that supports development of novel technologies to protect U.S. military personnel from threats posed by disease-carrying insect pests.



Flavocide® in a wearable emanator device

- » A wearable product containing Flavocide to control mosquitoes and other insect vectors of disease (Dengue, Malaria, etc)
- » Controlled Release Device developed by GearJump Technologies
- » A\$1.6M (US\$972,449) over three years
- » Collaborators:
 - U.S. Army Combat Capabilities Development Command, Maryland
 - Center for Medical, Agricultural and Veterinary Entomology, Agricultural Research Service, Florida
 - Walter Reed Army Institute of Research, Bangkok



Qcide® to provide residual control of bed bugs & crawling insects

- » A sprayable formulation of Qcide® to provide residual control of bed bug infestations, flies and other crawling insects
- » A\$1.4M (US\$892,492) over three years
- » Collaborators:
 - Walter Reed Army Institute of Research, Maryland,
 - Center for Medical, Agricultural and Veterinary Entomology, Florida

These grants are a strong validation of Bio-Gene's technology and will enable development of two innovative products containing Flavocide® and Qcide® for commercialisation in both the military and civilian markets.

Quarterly Updates (Appendix 4C) – Q2 FY25

Bio-Gene has established commercial partnerships with global partners, with additional commercial partners in progress.

Flavocide® Specification:

Flavocide pilot-scale batches screened, setting specification and use in GLP safety studies.

Process documentation for production of Flavocide was also finalised as the basis for future commercial scale production and to ensure product consistency and quality control.

Existing commercial and other partnerships:

Bio-Gene has continued to progress projects with previously announced commercial partners, including Clarke Mosquito Control (US), Evergreen Garden Care (UK, EU, AUS and NZ), and STK Bio-Ag (Israel).

These form the core of a strategy targeting professional, home garden and crop markets.

Flavocide GLP safety studies initiated:

- testing laboratories in Europe and India
- include dietary and metabolism tests and are an important part of the required list of registration enabling studies (APVMA)

Qcide® Production:

- 13th Qcide harvest and production of Qcide oil from Eucalyptus cloeziana leaf biomass from trees grown as an irrigated crop in Far North Queensland.
- Testing by JCU confirmed the required conditions to optimise oil extraction efficiency at scale from biomass.
- Programs to further improve yields and optimise the cost of production of Qcide continue.




Implementing program with Envu to develop Flavocide® formulations and evaluate use in mosquito management for professional pest management applications.

Qcide seed and seedling production:

- programs to support area expansion to meet future demand for Qcide oil.
- Conversion of some plantation area to a seed production area (SPA) has been completed
- Selection of superior trees from this SPA is also ongoing as the basis for collection of scions for a grafting program to provide early flowering trees for seed production

Flavocide Development Path

Regulatory approval of a formulated product is a two-step process.



* Timeline based on current estimates.

★ Key inflection milestones that will generate increased revenue and interest from commercial partners

Est. December 2025
1. Active constituent dossier submission

Est. April-June 2027
2. Active constituent approval

3. Product submissions

Est. 6 – 9 months based on current estimates.

4. End use product approval (est.)

Key Forward Milestones & News Flow

Bio-Gene has many catalysts to drive value over the next 18 months, with a strong pipeline of near-term news flow.

01

Flavocide & Qcide development

- ✓ Flavocide regulatory studies (multiple)
- ✓ Submission of Flavocide regulatory dossier in Australia
- ✓ Flavocide scale-up milestones
- ✓ Qcide regulatory development milestones
- ✓ Qcide scale-up and harvest/processing progress
- ✓ Regulatory milestones

02

Partnering & commercial

- ✓ New commercial partnerships
 - Crop & grain storage
 - Vector control
 - Consumer uses
- ✓ Expansion of current licenses
- ✓ Receipt of milestone payments
- ✓ Patents granted

03

Funding & other support

- ✓ Grant funding successes
- ✓ Synergistic program/product opportunities
- ✓ International funding support & validation

Contact

Tim Grogan
Managing Director & CEO
timg@bio-gene.com.au

Matthew Wright
NWR Communications
matt@nwrcommunications.com.au
0451 896 420

